BioNTech (BNTX) is a publicly traded Healthcare sector company. As of May 20, 2026, BNTX trades at $91.28 with a market cap of $22.47B and a P/E ratio of 0.00. BNTX moved +2.64% today. Year to date, BNTX is -6.70%; over the trailing twelve months it is -11.17%. Its 52-week range spans $79.52 to $129.27. Analyst consensus is strong buy with an average price target of $136.36. Rallies surfaces BNTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded BNTX stock?
Recent politician trading activity in BNTX includes disclosures from Josh Gottheimer and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
BNTX Key Metrics
Key financial metrics for BNTX
Metric
Value
Price
$91.28
Market Cap
$22.47B
P/E Ratio
0.00
EPS
$0.00
Dividend Yield
2.13%
52-Week High
$129.27
52-Week Low
$79.52
Volume
760.76K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$0
Gross Margin
0.00%
Congressional Trades in BNTX
Josh Gottheimer sale BNTX on Sep 3, 2024 (amount: $15.00K) for Joint.
Josh Gottheimer sale (partial) BNTX on Aug 30, 2024 (amount: $15.00K) for Joint.
Recent politician trading activity in BNTX includes disclosures from Josh Gottheimer and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BNTX?
Yes. Rallies tracks politician and congressional stock disclosures for BNTX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BNTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BNTX. It does not provide personalized investment advice.
